Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Southern California
Washington University School of Medicine
Deciphera Pharmaceuticals, LLC
Sumitomo Pharma America, Inc.
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
Emory University
Chang Gung Memorial Hospital
Laboratorio Elea Phoenix S.A.
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Thallion Pharmaceuticals